Clinical Nutrition For Alzheimer's Disease Market Size, Share & Trends Analysis Report By Product (Oral, Enteral), By Stage (Adult, Pediatric), By Sales Channel (Online Sales Channels, Retail Sales Channel), By Region, And Segment Forecasts, 2024 - 2030

Clinical Nutrition For Alzheimer's Disease Market Size, Share & Trends Analysis Report By Product (Oral, Enteral), By Stage (Adult, Pediatric), By Sales Channel (Online Sales Channels, Retail Sales Channel), By Region, And Segment Forecasts, 2024 - 2030

Clinical Nutrition For Alzheimer's Disease Market Growth & Trends

The global clinical nutrition for alzheimer's disease market size is expected to reach USD 1.7 billion by 2030, growing at a CAGR of 5.2% over the forecast period, according to a new report by Grand View Research, Inc. The market growth can be attributed to the increasing prevalence of Alzheimer’s and growing support from the government in the form of awareness programs. Moreover, growing R&D for dietary management of Alzheimer's patients contributes to growth. Alzheimer's disease is a chronic condition that leads to significant cognitive decline, impairing daily functions. Although current treatments can temporarily alleviate dementia symptoms and potentially decelerate the progression into more severe stages, Alzheimer's remains the sixth-leading cause of mortality in the U.S.

The financial implications of Alzheimer's on the healthcare system are significant, with costs amounting to billions of dollars and forecasts indicating a surge to over USD 1 trillion by 2050 due to an aging population. By 2030, the global economic impact of Alzheimer's dementia is expected to reach USD 2 trillion. Recognizing the urgency, leading players are introducing tailored clinical nutrition solutions to enhance patient adherence. An example of such innovation is Danone Nutricia's Souvenaid, a medical food product under the LipiDiDiet project, designed to improve daily functioning in early-stage Alzheimer's patients through a high-dose omega-3 formulation.

Moreover, the COVID-19 pandemic has significantly impacted the market. Supply chain disruptions led to shortages and delays in product availability, while lockdowns and restrictions limited patient access to essential nutrition therapies and routine healthcare. The increased emphasis on immune health heightened the demand for clinical nutrition products, despite economic challenges that affected funding and investment in research. The adoption of telehealth services surged, enabling continued access to nutritional guidance for Alzheimer's patients. However, delays in clinical trials and research projects slowed the development of new products. Overall, the pandemic underscored the vital role of nutrition in managing chronic diseases, potentially boosting future focus and investment in this field.

Some key players in the market, such as Danone S.A. (Nutricia), Pristine Organics, Alfasigma USA, Inc., are adopting various strategies such as product launches, partnerships, expansions, collaborations, and mergers & acquisitions. Through these strategic initiatives, industry players are trying to strengthen their positions and expand their customer base. For instance, in May 2024, Danone acquired Functional Formularies, a provider of whole food tube feeding solutions in the U.S., from Swander Pace Capital. This acquisition is a strategic component of Danone's Renew Strategy, enhancing the company's medical nutrition offerings in the U.S. market by broadening its portfolio of enteral tube feeding products

Clinical Nutrition For Alzheimer's Disease Market Report Highlights

• The market is segmented into oral, enteral, and parenteral based on product. Oral clinical nutrition dominated the market with a share of 49.51% in 2023.
• The increasing demand for oral nutrition is encouraging manufacturers to develop effective oral formulas capable of reducing Alzheimer's symptoms.
• The parenteral clinical nutrition segment is anticipated to witness the fastest growth at a CAGR of 6.3% from 2024 to 2030.
• The market is segmented into adults and pediatrics based on stage.
• The adults segment dominated the market in terms of revenue share in 2023 and is estimated to grow at the fastest CAGR of 5.3% over the forecast period, owing to the increasing prevalence of Alzheimer’s among adults.
• In addition, the growing awareness and education about the role of nutrition in managing Alzheimer's disease among this age group is expected to drive segment growth.
• The market is segmented by sales channel into online, retail, and institutional. The institutional sales channel held the largest share of 46.36% in 2023, owing to the rising adoption of clinical nutrition by hospitals for the treatment of Alzheimer’s disease.
• North America accounted for the largest share in 2023. This growth can be attributed to the increasing prevalence of Alzheimer’s disease in the region and the presence of prominent players in the market.
• However, Asia Pacific is anticipated to experience the fastest CAGR during the forecast period.

Please note The report will be delivered in 2-3 business days upon order notification.